Rangering i aksjer
#24690
ERYTECH Pharma S.A. is a clinical-stage biopharmaceutical company focused on... ERYTECH Pharma S.A. is a clinical-stage biopharmaceutical company focused on creating innovative therapies derived from red blood cells. These treatments target various types of cancer and rare (orphan) diseases, with the company operating in both France and the United States. Its primary experimental drug, eryaspase, is currently undergoing Phase 3 clinical trials for patients battling second-line pancreatic cancer. Furthermore, this candidate is also in Phase 2 development for triple-negative breast cancer and for individuals with second-line acute lymphoblastic leukemia. The company is additionally advancing erymethionase, a preclinical-stage product. This candidate utilizes methionine-gamma-lyase, encased within red blood cells, to specifically address cancers that are dependent on methionine for growth. Established in 2004, ERYTECH Pharma's corporate headquarters are situated in Lyon, France.
Aksjekurs
$0.95011029
Sist synkronisert: 2023-06-28
Handel ERYTECH Pharma S.A. (ERYP)
Pris ERYP pris med markedsverdi på B
Markedsverdi av ERYTECH Pharma S.A.(ERYP)
Markedsverdi: $57.72M
Per August 2026 har ERYTECH Pharma S.A. en markedsverdi på $57.72M. Dette gjør ERYTECH Pharma S.A. til det 24690th mest verdifulle selskapet i verden basert på markedsverdi ifølge våre data. Markedsverdi er den totale markedsverdien av et børsnotert selskaps utestående aksjer og brukes vanligvis til å måle hvor mye et selskap er verdt.
Markedsverdihistorikk for ERYTECH Pharma S.A. fra 2013 til 2026
ERYP sammenlignet med topp 5 mest populære stocks
| Pris på ERYP |
|
Eiendel B |
Markedsverdi for B |
Resultater |
|
|
|
|
$5.257T
|
+9,107,659.38%
|
|
|
|
|
$4.599T
|
+7,967,295.80%
|
|
|
|
|
$4.107T
|
+7,114,761.75%
|
|
|
|
|
$3.577T
|
+6,197,671.28%
|
|
|
|
|
$2.807T
|
+4,863,697.60%
|
